Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118508 · ClinicalTrials.gov registry record · NA
The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 87
- Enrollment target
NCT00118508 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 87 participants.
The verdict
NCT00118508, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of once weekly risedronate in the prevention and treatment of bone loss in premenopausal and newly menopausal women with breast cancer who have received chemotherapy. The hypothesis is that bisphosphonate therapy will prevent bone loss at clinically relevant sites, such as the hip and spine. The investigators also hypothesize that there will be a correlation between biochemical markers of bone turnover and changes in bone mineral density.
Interventions
- DRUG risedronate (including placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118508
The ClinicalTrials.gov registry entry for NCT00118508 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risedronate (including placebo) is the first listed.
NCT00118508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118508 about?
NCT00118508 is a clinical study titled "The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)". The purpose of this study is to evaluate the effectiveness of once weekly risedronate in the prevention and treatment of bone loss in premenopausal and newly menopausal women with breast cancer who have received chemotherapy. The hypothesis is that bisphosphonate therapy will prevent bone loss at c...
What is the current status of trial NCT00118508?
This trial is currently completed. It is a NA study. The enrollment target is 87 participants. The study started on 2003-05. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00118508?
The interventions under investigation include: risedronate (including placebo) (DRUG).
Who is sponsoring clinical trial NCT00118508?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.